We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · September 04, 2022

Effect of Mesalazine Treatment on GI Symptoms and Rectal Biomarkers of Immune Activity in IBS

Alimentary Pharmacology & Therapeutics

 

Additional Info

Disclosure statements are available on the authors' profiles:

Alimentary Pharmacology & Therapeutics
Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity
Aliment. Pharmacol. Ther. 2022 Sep 01;56(6)968-979, V Castro Tejera, L Öhman, L Aabakken, B Fellström, T Hausken, Ø Hovde, JP Hreinsson, G Lindberg, P Venge, M Simrén, H Törnblom

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading